and carbimazole have
been used for the treatment of hyperthyroidism during
pregnancy. The pharmacokinetics of MMI is not altered
in pregnancy; it has been reported that serum PTU
concentrations may be lower in the third than in the
first and second trimesters of gestation (19). Use of PTU
should be restricted to first trimester of pregnancy, after
which change to MMI is recommended